These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 1297406)

  • 1. Studies on the minimum requirements for in vitro "cure" of tumor cells by cytotoxic T lymphocytes.
    Miki S; Ksander B; Streilein JW
    Reg Immunol; 1992; 4(6):352-62. PubMed ID: 1297406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Failure of infiltrating precursor cytotoxic T cells to acquire direct cytotoxic function in immunologically privileged sites.
    Ksander BR; Streilein JW
    J Immunol; 1990 Oct; 145(7):2057-63. PubMed ID: 1975822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infiltration and accumulation of precursor cytotoxic T-cells increase with time in progressively growing ocular tumors.
    Ksander BR; Bando Y; Acevedo J; Streilein JW
    Cancer Res; 1991 Jun; 51(12):3153-8. PubMed ID: 1904003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local T helper cell signals by lymphocytes infiltrating intraocular tumors.
    Ksander BR; Acevedo J; Streilein JW
    J Immunol; 1992 Mar; 148(6):1955-63. PubMed ID: 1531848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete elimination ('cure') of progressively growing intraocular tumors by local injection of tumor-specific CD8+ T lymphocytes.
    Miki S; Ksander B; Streilein JW
    Invest Ophthalmol Vis Sci; 1993 Dec; 34(13):3622-34. PubMed ID: 8258521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recovery of activated cytotoxic T cells from minor H incompatible tumor graft rejection sites.
    Ksander BR; Streilein JW
    J Immunol; 1989 Jul; 143(2):426-31. PubMed ID: 2500481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of cytotoxic T cell responses to intracameral allogeneic tumors.
    Ksander BR; Streilein JW
    Invest Ophthalmol Vis Sci; 1989 Feb; 30(2):323-9. PubMed ID: 2492486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T lymphocytes infiltrating sites of tumor rejection and progression display identical V beta usage but different cytotoxic activities.
    Kurt RA; Park JA; Panelli MC; Schluter SF; Marchalonis JJ; Carolus B; Akporiaye ET
    J Immunol; 1995 Apr; 154(8):3969-74. PubMed ID: 7706735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential requirement for CD4 help in the development of an antigen-specific CD8+ T cell response depending on the route of immunization.
    Bour H; Horvath C; Lurquin C; Cerottini JC; MacDonald HR
    J Immunol; 1998 Jun; 160(11):5522-9. PubMed ID: 9605156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
    Li Y; McGowan P; Hellström I; Hellström KE; Chen L
    J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
    Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W
    J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of specific T helper cell activity in mice bearing alloantigenic tumors in the anterior chamber of the eye.
    Bando Y; Ksander BR; Streilein JW
    Eur J Immunol; 1991 Aug; 21(8):1923-31. PubMed ID: 1831132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapeutic elimination of syngeneic tumors in vivo by cytotoxic T lymphocytes generated in vitro from lymphocytes from the draining lymph nodes of tumor-bearing mice.
    Lynch DH; Miller RE
    Eur J Immunol; 1991 Jun; 21(6):1403-10. PubMed ID: 1904359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
    Shu SY; Chou T; Rosenberg SA
    J Immunol; 1987 Jul; 139(1):295-304. PubMed ID: 2953816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
    Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
    Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M; Plautz GE; Shu S
    Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages.
    Maas RA; Roest PA; Becker MJ; Weimar IS; Dullens HF; Den Otter W
    Immunobiology; 1992 Nov; 186(3-4):214-29. PubMed ID: 1490728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo.
    Ley V; Langlade-Demoyen P; Kourilsky P; Larsson-Sciard EL
    Eur J Immunol; 1991 Mar; 21(3):851-4. PubMed ID: 2009918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Termination of immune privilege in the anterior chamber of the eye when tumor-infiltrating lymphocytes acquire cytolytic function.
    Ksander BR; Mammolenti MM; Streilein JW
    Transplantation; 1991 Jul; 52(1):128-33. PubMed ID: 1907041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
    Shu S; Krinock RA; Matsumura T; Sussman JJ; Fox BA; Chang AE; Terman DS
    J Immunol; 1994 Feb; 152(3):1277-88. PubMed ID: 8301131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.